{"id":"NCT00857220","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia","officialTitle":"A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2011-10","completion":"2011-10","firstPosted":"2009-03-06","resultsPosted":"2013-07-22","lastUpdate":"2017-10-26"},"enrollment":304,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Insomnia","Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"eszopiclone","otherNames":[]},{"type":"DRUG","name":"eszopiclone","otherNames":[]}],"arms":[{"label":"2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)","type":"EXPERIMENTAL"}],"summary":"A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.","primaryOutcome":{"measure":"Overall Incidence of Adverse Events","timeFrame":"12 Months (from the 1st dose to the end of study)","effectByArm":[{"arm":"2mg Eszopiclone (6-11yrs), 3mg Eszopiclone (12-17yrs)","deltaMin":212,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":15},"locations":{"siteCount":89,"countries":["United States"]},"refs":{"pmids":["25266438"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":303},"commonTop":["Headache","Dysgeusia","Dizziness","Nasopharyngitis","Abdominal Pain Upper"]}}